A potential therapeutic agent for sickle cell anaemia by Nature Research (16552612)

“…</p><h2>Other Information</h2><p>Published in: QScience.com Highlights, Published by Nature Research for Hamad bin Khalifa University Press (HBKU Press)<br>License: <a href="http://creativecommons.org/licenses/by/4.0" target="_blank">http://creativecommons.org/licenses/by/4.0</a><br></p>…”

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…AGs have played a significant role in clinical practice in recent years.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…AGs have played a significant role in clinical practice in recent years.…”

Supplementary figure 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma by Douglas W. Sborov (10760514)

Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency by Wan-Ching Yen (11520727)

Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplementary Table 1 from A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice by Jo Waaler (1970758)

Therapeutic Administration Success Rates. by Alani Mohanad Khalid Ahmed (22693496)

Figure S3 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)

Figure S7 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)

Figure S6 from Circadian Oscillations Persist in Cervical and Esophageal Cancer Cells Displaying Decreased Expression of Tumor-Suppressing Circadian Clock Genes by Pauline J. van der Watt (15068109)